Stock Analysis on Net

Celgene Corp. (NASDAQ:CELG)

$22.49

This company has been moved to the archive! The financial data has not been updated since October 31, 2019.

Adjustments to Financial Statements

Microsoft Excel

Paying users area


We accept:

Visa Mastercard American Express Maestro Discover JCB PayPal Apple Pay Google Pay
Visa Secure Mastercard Identity Check American Express SafeKey

Adjustments to Current Assets

Celgene Corp., adjusted current assets

US$ in millions

Microsoft Excel
Dec 31, 2018 Dec 31, 2017 Dec 31, 2016 Dec 31, 2015 Dec 31, 2014
As Reported
Current assets
Adjustments
Add: Allowance for doubtful accounts
Less: Current deferred tax assets1
After Adjustment
Adjusted current assets

Based on: 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31).

1 Current deferred tax assets. See details »


Adjustments to Total Assets

Celgene Corp., adjusted total assets

US$ in millions

Microsoft Excel
Dec 31, 2018 Dec 31, 2017 Dec 31, 2016 Dec 31, 2015 Dec 31, 2014
As Reported
Total assets
Adjustments
Add: Operating lease right-of-use asset (before adoption of FASB Topic 842)1
Add: Allowance for doubtful accounts
Less: Current deferred tax assets2
Less: Non-current deferred tax assets (included in Other non-current assets)3
After Adjustment
Adjusted total assets

Based on: 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31).

1 Operating lease right-of-use asset (before adoption of FASB Topic 842). See details »

2 Current deferred tax assets. See details »

3 Non-current deferred tax assets (included in Other non-current assets). See details »


Adjustments to Current Liabilities

Celgene Corp., adjusted current liabilities

US$ in millions

Microsoft Excel
Dec 31, 2018 Dec 31, 2017 Dec 31, 2016 Dec 31, 2015 Dec 31, 2014
As Reported
Current liabilities
Adjustments
Less: Current deferred tax liabilities1
Less: Current portion of deferred revenue
After Adjustment
Adjusted current liabilities

Based on: 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31).

1 Current deferred tax liabilities. See details »


Adjustments to Total Liabilities

Celgene Corp., adjusted total liabilities

US$ in millions

Microsoft Excel
Dec 31, 2018 Dec 31, 2017 Dec 31, 2016 Dec 31, 2015 Dec 31, 2014
As Reported
Total liabilities
Adjustments
Add: Operating lease liability (before adoption of FASB Topic 842)1
Less: Current deferred tax liabilities2
Less: Non-current deferred tax liabilities3
Less: Deferred revenue
After Adjustment
Adjusted total liabilities

Based on: 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31).

1 Operating lease liability (before adoption of FASB Topic 842). See details »

2 Current deferred tax liabilities. See details »

3 Non-current deferred tax liabilities. See details »


Adjustments to Stockholders’ Equity

Celgene Corp., adjusted stockholders’ equity

US$ in millions

Microsoft Excel
Dec 31, 2018 Dec 31, 2017 Dec 31, 2016 Dec 31, 2015 Dec 31, 2014
As Reported
Stockholders’ equity
Adjustments
Less: Net deferred tax asset (liability)1
Add: Allowance for doubtful accounts
Add: Deferred revenue
After Adjustment
Adjusted stockholders’ equity

Based on: 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31).

1 Net deferred tax asset (liability). See details »


Adjustments to Capitalization Table

Celgene Corp., adjusted capitalization table

US$ in millions

Microsoft Excel
Dec 31, 2018 Dec 31, 2017 Dec 31, 2016 Dec 31, 2015 Dec 31, 2014
As Reported
Short-term borrowings and current portion of long-term debt
Long-term debt, net of discount, excluding current portion
Total reported debt
Stockholders’ equity
Total reported capital
Adjustments to Debt
Add: Operating lease liability (before adoption of FASB Topic 842)1
Adjusted total debt
Adjustments to Equity
Less: Net deferred tax asset (liability)2
Add: Allowance for doubtful accounts
Add: Deferred revenue
Adjusted stockholders’ equity
After Adjustment
Adjusted total capital

Based on: 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31).

1 Operating lease liability (before adoption of FASB Topic 842). See details »

2 Net deferred tax asset (liability). See details »


Adjustments to Revenues

Celgene Corp., adjusted net product sales

US$ in millions

Microsoft Excel
12 months ended: Dec 31, 2018 Dec 31, 2017 Dec 31, 2016 Dec 31, 2015 Dec 31, 2014
As Reported
Net product sales
Adjustment
Add: Increase (decrease) in deferred revenue
After Adjustment
Adjusted net product sales

Based on: 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31).


Adjustments to Reported Income

Celgene Corp., adjusted net income

US$ in millions

Microsoft Excel
12 months ended: Dec 31, 2018 Dec 31, 2017 Dec 31, 2016 Dec 31, 2015 Dec 31, 2014
As Reported
Net income
Adjustments
Add: Deferred income tax expense (benefit)1
Add: Increase (decrease) in allowance for doubtful accounts
Add: Increase (decrease) in deferred revenue
Add: Other comprehensive income (loss)
After Adjustment
Adjusted net income

Based on: 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31).

1 Deferred income tax expense (benefit). See details »